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Biomarkers Are Here to Stay for Clinical Research and
Standard Care
Paul A. Bunn, Jr, MD, Fred R. Hirsch, MD, PhD, Robert C. Doebele, MD, PhD,
D. Ross Camidge, MD, PhD, Marileila Varella-Garcia, PhD, and Wilbur Franklin, MD
Subramanian et al.1 reviewed the status of lung cancer clinical trials active in 2009 bysearching the ClinicalTrials.gov website. This website does not include every trial
enrolling lung cancer patients, but the results are quite sobering. The data suggest that
there are at least 500 ongoing therapeutic trials for non-small cell lung cancer (NSCLC)
worldwide. Of these, about 240 were phase II trials and about 77 were phase III.
Enrollment averaged 66 patients in phase II trails and 600 patients in phase III. Phase II
trials were open about 2 years and phase III trials about 3 years. These data suggest that
approximately 31,000 lung cancer patients are enrolled onto a clinical trial each year.
These data focus on trials in the US, but half of the studies enrolled patients outside the
US. There are more than 220,000 new lung cancer cases in the US each year and more
than 1.2 million worldwide.2,3 Thus, the fraction of patients who are enrolled on a
therapeutic clinical trial remains small. These data are consistent with data from US
cooperative groups, suggesting that less than 5% of patients diagnosed with lung
cancer are enrolled on a therapeutic trial.4 These numbers are even smaller for
early-stage lung cancer.
The data regarding biomarkers were also striking. A biomarker analysis was
included as a study objective in only about one-third of the trials. Biomarker-based patient
selection was used in only 7% of the trials! We know that the majority of phase III trials
fail to meet their primary objective. We need to improve our strategies.
Why does all this matter? Now is the time for paradigm shifts in the way we conduct
clinical trial research and the way we treat patients. In the new era of personalized
medicine—more than ever—tissue is the issue. Activating mutations in the epidermal
growth factor receptor (EGFR) were shown to be associated with benefit from the EGFR
tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib in 2004.5,6 Since that time, several
randomized trials have shown that these EGFR TKIs provide higher response rates
(70%), longer progression-free survival, better quality of life, and less severe toxicity
compared with platinum doublet chemotherapy in chemonaive patients with advanced
NSCLC whose tumors harbor activating EGFR mutations.7–11 In contrast, chemotherapy
provided higher response rates and longer progression-free survival in patients with EGFR
wild-type tumors. Activation of the ALK tyrosine kinase oncogene in lung cancer by
fusion to the EML4 gene or other partners was first reported in 2007.12 Early studies of
the ALK tyrosine kinase inhibitor termed crizotinib (PF-02341066) showed tumor
regression in 39 of 41 patients and objective response by RECIST criteria in 63% in
patients whose tumors harbor ALK gene rearrangements.13 Thus, selection by analysis of
molecular features improved outcome.
In patients with EGFR wild-type tumors, EGFR TKIs improved survival in the
maintenance and second-line and third-line settings compared with best supportive care,
but the hazard rate reductions were less than in EGFR-mutant tumors.14,15 Whether this
represents genuine benefit in the wild-type population or a false-negative rate associated
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with some methods of mutation detection continues to be
debated. In the EGFR wild-type population, studies have yet
to identify other predictive biomarkers although proteomic
analysis of serum protein holds some promise.16,17
Can biomarker studies be performed routinely on tumor
biopsies obtained for routine diagnosis? Many of the original
studies of EGFR TKIs retrospectively obtained biopsies, but
these were available in only about 25% of cases. Prospective
studies from Spain, the US, and Asia showed that up to 80%
of original biopsies could be successfully tested and that
mutation, fluorescence in situ hybridization and Immunohis-
tochemistry data could be available within 5 to 7 working
days.18–20 The Biomarker-Integrated Approaches of Targeted
Therapy for Lung Cancer Elimination protocol from the
M. D. Anderson Cancer Center extended these observations
to the second-line setting by which they established a biomar-
ker-driven protocol that required a new core needle biopsy
and a panel of biomarkers to be completed within 2 weeks.20
The trial enrolled 253 patients, and a new biopsy was suc-
cessfully obtained in 239 (94%). Biomarker results were
available in all but 29 patients. These data demonstrated that
the biomarker approach can work in both the first- and
second-line setting and that rebiopsy can be performed where
necessary. These observations have been extended to ran-
domized phase III trials in all stages. In the early-stage
adjuvant setting in which postresection tissue is easily avail-
able, the RADIANT trial evaluates the role of erlotinib and
required tissue analysis. The trial completed its accrual in a
timely manner. Preliminary biomarker data have been pre-
sented.21 The MAGE A3 vaccine trial sponsored by Glaxo-
SmithKline has also required tissue results for protocol ran-
domization. The Cancer and Leukemia Group B and
Southwest Oncology Group have pilot adjuvant trials in stage
I disease in which the primary end point is biomarker depen-
dent. In stage III and IV disease, the Southwest Oncology
Group has a trial evaluating biomarkers to determine eligi-
bility for a first-line trial evaluating cetuximab. The Spanish
group has a trial requiring mutation analyses to be eligible for
a trial evaluating erlotinib. Boehringer-Ingelheim is support-
ing a first-line trial with prospective EGFR mutation analysis
as an eligibility criterion for a trial evaluating an irreversible
pan-HER inhibitor called BIBW2992. Pfizer has a random-
ized phase III second-line trial that requires confirmed ALK
gene rearrangements through FISH for study entry. Multiple
other similar biomarker selected studies are now ongoing,
which cannot be detailed because of space constraints.
Equally important are countless other studies that do not
collect tissues, do not analyze biomarkers, and will do little to
improve therapeutic outcomes.
There is no doubt that prospective collection and anal-
ysis of biomarkers to select patients for specific interventions
takes both time and money. It may seem scary that a large
potential market for a drug is being whittled away even
before the drug has achieved a license and that there seem to
be many different biomarkers and methods of detecting and
quantifying those biomarkers to choose from. But biomarkers
are here to stay. Personalized medicine for lung cancer is
actually happening. Having another rapidly completed nega-
tive phase III study in an unselected population represents a
tremendous waste of time, money, and, most precious of
resources, patients. A positive biomarker-selected registration
study does not preclude post-licensing exploration of other
groups, which may have a more marginal benefit from the
drug. Similarly, even a negative biomarker-selected study
would add considerably more to the development plans for a
drug, in terms of defining directions not to go in, than a
negative study in an unselected population. If we are to learn
by our mistakes, we must improve our therapeutic develop-
ment strategy by the early incorporation of biomarkers into
our clinical trials. Testing rational and novel biomarkers early
in the development of molecularly targeted agents will pro-
vide insight into mechanisms of action and resistance, in-
crease efficacy, and decrease unnecessary toxicity for our
patients and may ultimately rescue the approval of drugs
otherwise doomed to fail in an unselected population of
patients. We simply can no longer afford to repeat the same
drug development strategy by conducting clinical trials in
NSCLC as if this were a single disease entity.
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